Skip to content
No results
  • News
  • Press Releases
  • Business
  • Research
  • Regulatory
  • Events and Conferences

Preventive Medicine 2023

We use cookies to ensure that we give you the best experience on our website.
  • About Us
  • Contact Us
the-pharma-data-logo-color

Preventive Medicine 2023

  • News
  • Press Releases
  • Business
  • Research
  • Regulatory
  • Events and Conferences
the-pharma-data-logo-color
  • Research

Roche announces positive data from global phase III programme for crovalimab in PNH, a rare life-threatening blood condition

  • ByThe Pharma Data
  • OnFebruary 7, 2023

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the global phase III COMMODORE 2 study, evaluating the…

Read More
  • Regulatory

Forxiga approved in the EU for the treatment of symptomatic chronic heart failure

  • ByThe Pharma Data
  • OnFebruary 7, 2023

First and only heart failure therapy with proven mortality benefitacross the full ejection fraction range  Forxiga (dapagliflozin) has been approved in…

Read More
  • Research

Scientists pinpoint protein that helps cancer-causing viruses evade immune response

  • ByThe Pharma Data
  • OnFebruary 7, 2023

The viruses Kaposi sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) have been linked to several cancers. For the first time,…

Read More
WHO urges more effective prevention of injuries and violence causing 1 in 12 deaths worldwide
  • News

Longstanding WHO partners to enter into official relations with the OrganizationWHOLongstanding WHO partners to enter into official relations with the Organization

  • ByThe Pharma Data
  • OnFebruary 7, 2023

Geneva – WHO’s Executive Board today welcomed the Carter Center, Inc. and the NCD Alliance into official relations with WHO.…

Read More
  • Research

GSK announces results from 17-year retrospective study on US clinical trial diversity

  • ByThe Pharma Data
  • OnFebruary 7, 2023

GSK plc (LSE/NYSE: GSK) today announced results from a retrospective study on clinical trial diversity, investigating the historical representation of…

Read More
  • Regulatory

Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA

  • ByThe Pharma Data
  • OnFebruary 7, 2023

 Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the US Food and Drug Administration (FDA)…

Read More
  • Regulatory

Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU

  • ByThe Pharma Data
  • OnFebruary 7, 2023

Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on…

Read More
  • Regulatory

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

  • ByThe Pharma Data
  • OnFebruary 7, 2023

 Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the…

Read More
  • Research

Transforming the way cancer vaccines are designed and made

  • ByThe Pharma Data
  • OnFebruary 6, 2023

A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International…

Read More
  • News

WHO launches new roadmap on breast cancer

  • ByThe Pharma Data
  • OnFebruary 6, 2023

The World Health Organization (WHO) released a new Global Breast Cancer Initiative Framework today providing a roadmap to attain the targets to…

Read More
  • Business

U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

  • ByThe Pharma Data
  • OnFebruary 6, 2023

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the…

Read More
  • Research

Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®

  • ByThe Pharma Data
  • OnFebruary 6, 2023

 Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx® (secukinumab) in moderate-to-severe hidradenitis…

Read More
1 2 3 4 … 96
Next
Pediatric Academic Societies Meetimg (PAS) 2023
Global Pharma & Drug Delivery Summit 2023
ACPM 2023
The 15th Paris Hepatology Conference 2023
ASGBI annual conference 2023
37th NASPAG Annual Clinical & Research Meeting 2023
TBS23
18th Congress MESOT 2023

About

The Pharma Data Is An Information-Centric Website Focused Mainly On The Pharmaceutical Industry Online It Is A B2B Platform Mainly Focused On The Latest Pharmaceutical News, Press Release, Industry-Related Updates, Events, And Conferences. With The Pharma Data, You Can Get All Information That Happens In The Pharmaceutical Industry.

Advertise With Us: marketing@thepharmadata.com

Quick Links

  • News
  • Press Releases
  • Business
  • Research
  • Regulatory
  • Events and Conferences
  • About Us
  • Contact Us
  • Privacy Policy
  • Disclaimer
  • Terms and Conditions

Copyright © 2023 | The Pharma Data | Marnet Technologies Pvt Ltd. | Al Rights Reserved

Facebook Twitter LinkedIn